EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma

Phase-II-Studie zu Avelumab und Trastuzumab mit FOLFOX-Chemotherapie bei zuvor unbehandeltem HER2-amplifiziertem metastasiertem gastroösophagealem Adenokarzinom

Michael S Lee, Joseph Chao, Mary F Mulcahy, Pashtoon M Kasi, Angela T Alistar, Sarbajit Mukherjee iD, Mehmet Akce, Dominic T Moore, Autumn J McRee iD, Ashwin Somasundaram iD

The Oncologist · 04.07.2025 · 30 (7)

DOI: 10.1093/oncolo/oyaf195 ↗

Auf einen Blick

In einer Phase-II-Studie zeigte die Kombination aus Avelumab, Trastuzumab und mFOLFOX6 bei zuvor unbehandeltem HER2-amplifiziertem metastasiertem gastroösophagealem Adenokarzinom Aktivität. Die 24-Wochen-Ansprechrate betrug 61 %.

Fragestellung

Wie wirksam und verträglich ist Avelumab plus Trastuzumab und mFOLFOX6 bei zuvor unbehandeltem HER2-amplifiziertem metastasiertem gastroösophagealem Adenokarzinom?

Methode

Multizentrische, einarmige Phase-II-Studie (HCRN GI17-319) mit 6-Personen-Sicherheitsrun-in; Avelumab, Trastuzumab und mFOLFOX6, danach Erhaltung mit Avelumab + Trastuzumab.

Ergebnisse

18 Patient:innen wurden 4/2019-8/2020 eingeschlossen. 24-Wochen-Ansprechrate 11/18 (61 %; 95 %-KI 39 %-84 %), bestätigte Gesamtansprechrate 9/18 (50 %). Medianes PFS 8,0 Monate (95 %-KI 5,3-NA), medianes OS 13,1 Monate (95 %-KI 11,5-NA).

Einschränkungen

Die Rekrutierung wurde nach der ersten Simon-Phase aus nicht mit Sicherheit oder Wirksamkeit zusammenhängenden Gründen beendet.

Schlussfolgerung der Autor:innen

Die Kombination zeigte laut Autor:innen Aktivität mit vertretbarer Ansprechrate und medianem PFS. Die Ergebnisse stützen weitere Studien und die zukünftige Prüfung von Avelumab in diesem Setting.

Kernaussagen

  • 24-Wochen-Ansprechrate: 61 % (11/18)
  • Bestätigte Gesamtansprechrate: 50 % (9/18)
  • Kein neues Sicherheitssignal berichtet

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 17.07.2025. Verfasst von Michael S Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innovative Medicine Research & Development, Johnson and Johnson Innovative Medicine Research & Development, LLC, Spring House, PA, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized, Trastuzumab, Esophageal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EMD Serono, NCI NIH HHS, Germany.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab and multiagent chemotherapy have been the standard of care for the 20-30% of metastatic gastric and esophageal adenocarcinomas that overexpress HER2. Preclinical data show that trastuzumab requires a functional adaptive immune system for efficacy, suggesting synergy of trastuzumab combined with immune checkpoint inhibitors, further supported by current clinical studies.

Methods

HCRN GI17-319 was a multicenter, single-arm, phase II clinical trial with a prespecified 6-subject safety run-in of the anti-PD-L1 antibody avelumab, combined with trastuzumab and mFOLFOX6, in previously untreated, metastatic, HER2-amplified gastric and esophageal adenocarcinomas. The primary endpoint was the best overall response within 24 weeks. Subjects received 9 cycles of induction avelumab, trastuzumab, and mFOLFOX6, followed by maintenance avelumab + trastuzumab. The study was initially designed as a Simon’s 2-stage trial, but enrollment was stopped after the 18-subject first stage for reasons unrelated to safety or efficacy.

Results

A total of 18 subjects, including the 6-subject safety run-in, were enrolled 4/2019-8/2020. The 24-week response rate was 11/18 (61%; 95% CI: 39%-84%), and the confirmed overall response rate is 9/18 (50%). With a median follow-up of 14.6 months, the median PFS was 8.0 months (95% CI: 5.3-NA) and median OS was 13.1 months (95% CI: 11.5-NA). The regimen was well tolerated, without any new safety signals.

Conclusions

The combination of avelumab, trastuzumab, and FOLFOX chemotherapy demonstrated some activity, with a reasonable response rate and median PFS. These outcomes provide some support to other clinical trials of similar agents and support the future evaluation of adding avelumab in this setting. NCT03783936.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedTrastuzumabEsophageal NeoplasmsAdenocarcinomaStomach NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleLeucovorinMiddle AgedMaleFluorouracilAgedOrganoplatinum CompoundsAdult

Stichwörter der Autor:innen

HER2esophageal cancergastric cancerimmunotherapytrastuzumab

Substanzen

Antibodies, Monoclonal, HumanizedTrastuzumabLeucovorinFluorouracilErb-b2 Receptor Tyrosine KinasesOrganoplatinum CompoundsavelumabERBB2 protein, human

Autor:innen und Institutionen

  • Department of Innovative Medicine Research & Development, Johnson and Johnson Innovative Medicine Research & Development, LLC, Spring House, PA, USA.
  • Department of Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Department of Medicine, Northwestern University, Chicago, IL, USA.
  • Department of Medicine, Morristown Medical Center, Morristown, NJ, USA.
  • Department of Medicine, Roswell Park Cancer Center, Buffalo, NY, USA.
  • Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

ORCID-Profile: Sarbajit Mukherjee, Autumn J McRee, Ashwin Somasundaram

Förderung

  • EMD Serono
  • NCI NIH HHS
  • Germany
  • University of North Carolina Lineberger Comprehensive Cancer Center
  • Darmstadt
  • Pfizer
  • Merck KGaA

Zitieren

APA

Lee, M. S., Chao, J., Mulcahy, M. F., Kasi, P. M., Alistar, A. T., Mukherjee, S., Akce, M., Moore, D. T., McRee, A. J., & Somasundaram, A. (2025). Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma. The Oncologist, 30(7). https://doi.org/10.1093/oncolo/oyaf195

Vancouver

Lee MS, Chao J, Mulcahy MF, Kasi PM, Alistar AT, Mukherjee S, et al. Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma. The Oncologist. 2025;30(7). doi:10.1093/oncolo/oyaf195

BibTeX
@article{Lee2025,
  author = {Lee, Michael S and Chao, Joseph and Mulcahy, Mary F and Kasi, Pashtoon M and Alistar, Angela T and Mukherjee, Sarbajit and Akce, Mehmet and Moore, Dominic T and McRee, Autumn J and Somasundaram, Ashwin},
  title = {Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {7},
  doi = {10.1093/oncolo/oyaf195}
}
Kostenlos starten →